We can’t show the full text here under this license.
Abstract
A 23-year-old woman with probable slowly progressive type 1 diabetes mellitus (SPIDDM) experienced significant improvements in glycemic levels and weight after initiating oral semaglutide.
- The patient had poor glycemic and weight control despite being treated with insulin, dapagliflozin, and metformin.
- Following treatment with oral semaglutide, insulin could be discontinued.
- Improvements in eating behavior were also observed after starting oral semaglutide.
- GLP-1 receptor agonists may represent a beneficial therapeutic option for glucose and weight management in SPIDDM.
Simplified